vs
Arcellx, Inc.（ACLX）与AGENUS INC（AGEN）财务数据对比。点击上方公司名可切换其他公司
AGENUS INC的季度营收约是Arcellx, Inc.的20.7倍（$34.2M vs $1.7M）。AGENUS INC净利率更高（-31.0% vs -3513.4%，领先3482.4%）。AGENUS INC同比增速更快（27.5% vs -89.2%）。过去两年AGENUS INC的营收复合增速更高（10.5% vs -79.5%）
Arcellx, Inc.是一家处于临床阶段的生物技术企业，专注开发用于治疗血液恶性肿瘤、实体瘤等难治性癌症的CAR-T细胞疗法，其核心管线针对肿瘤领域未被满足的医疗需求，服务全球患者群体。
Agenus Inc.是一家总部位于美国马萨诸塞州列克星敦的生物技术公司，核心业务聚焦免疫治疗领域，尤其专注于利用人体免疫系统控制或治愈癌症的肿瘤免疫治疗。公司目前正在研发检查点调节剂、个性化抗癌疫苗，以及可适配多种疫苗的免疫佐剂，其中检查点调节剂作为当前进展迅速的方向，早期产品已为患者带来突破性临床获益。
ACLX vs AGEN — 直观对比
营收规模更大
AGEN
是对方的20.7倍
$1.7M
营收增速更快
AGEN
高出116.6%
-89.2%
净利率更高
AGEN
高出3482.4%
-3513.4%
两年增速更快
AGEN
近两年复合增速
-79.5%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $1.7M | $34.2M |
| 净利润 | $-58.1M | $-10.6M |
| 毛利率 | — | — |
| 营业利润率 | -3850.2% | 42.1% |
| 净利率 | -3513.4% | -31.0% |
| 营收同比 | -89.2% | 27.5% |
| 净利润同比 | -23.4% | 77.3% |
| 每股收益（稀释后） | $-1.01 | $0.09 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ACLXAGEN
| Q4 25 | $1.7M | $34.2M | ||
| Q3 25 | $4.9M | $30.2M | ||
| Q2 25 | $7.6M | $25.7M | ||
| Q1 25 | $8.1M | $24.1M | ||
| Q4 24 | $15.3M | $26.8M | ||
| Q3 24 | $26.0M | $25.1M | ||
| Q2 24 | $27.4M | $23.5M | ||
| Q1 24 | $39.3M | $28.0M |
净利润ACLXAGEN
| Q4 25 | $-58.1M | $-10.6M | ||
| Q3 25 | $-55.8M | $63.9M | ||
| Q2 25 | $-52.8M | $-30.0M | ||
| Q1 25 | $-62.3M | $-26.4M | ||
| Q4 24 | $-47.1M | $-46.8M | ||
| Q3 24 | $-25.9M | $-67.2M | ||
| Q2 24 | $-27.2M | $-54.8M | ||
| Q1 24 | $-7.2M | $-63.5M |
毛利率ACLXAGEN
| Q4 25 | — | — | ||
| Q3 25 | — | 97.9% | ||
| Q2 25 | — | 99.1% | ||
| Q1 25 | — | 99.4% | ||
| Q4 24 | — | 99.6% | ||
| Q3 24 | — | 99.4% | ||
| Q2 24 | — | 99.5% | ||
| Q1 24 | — | 99.6% |
营业利润率ACLXAGEN
| Q4 25 | -3850.2% | 42.1% | ||
| Q3 25 | -1248.3% | -15.0% | ||
| Q2 25 | -777.4% | -65.0% | ||
| Q1 25 | -847.6% | -55.3% | ||
| Q4 24 | -348.2% | -96.5% | ||
| Q3 24 | -129.1% | -125.5% | ||
| Q2 24 | -127.8% | -128.4% | ||
| Q1 24 | -40.3% | -117.4% |
净利率ACLXAGEN
| Q4 25 | -3513.4% | -31.0% | ||
| Q3 25 | -1127.1% | 211.4% | ||
| Q2 25 | -698.6% | -116.8% | ||
| Q1 25 | -766.0% | -109.6% | ||
| Q4 24 | -308.4% | -174.4% | ||
| Q3 24 | -99.4% | -267.7% | ||
| Q2 24 | -99.3% | -233.1% | ||
| Q1 24 | -18.3% | -226.6% |
每股收益（稀释后）ACLXAGEN
| Q4 25 | $-1.01 | $0.09 | ||
| Q3 25 | $-0.99 | $1.94 | ||
| Q2 25 | $-0.94 | $-1.00 | ||
| Q1 25 | $-1.13 | $-1.03 | ||
| Q4 24 | $-0.87 | $-1.95 | ||
| Q3 24 | $-0.48 | $-3.08 | ||
| Q2 24 | $-0.51 | $-2.52 | ||
| Q1 24 | $-0.14 | $-3.04 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $450.3M | $3.0M |
| 总债务越低越好 | — | $44.7M |
| 股东权益账面价值 | $402.4M | $-271.1M |
| 总资产 | $604.0M | $226.8M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ACLXAGEN
| Q4 25 | $450.3M | $3.0M | ||
| Q3 25 | $461.4M | $3.5M | ||
| Q2 25 | $453.1M | $9.5M | ||
| Q1 25 | $543.3M | $18.5M | ||
| Q4 24 | $587.4M | $40.4M | ||
| Q3 24 | $574.3M | $44.8M | ||
| Q2 24 | $516.7M | $93.7M | ||
| Q1 24 | $573.9M | $52.9M |
总债务ACLXAGEN
| Q4 25 | — | $44.7M | ||
| Q3 25 | — | $34.2M | ||
| Q2 25 | — | $33.9M | ||
| Q1 25 | — | $33.6M | ||
| Q4 24 | — | $33.2M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益ACLXAGEN
| Q4 25 | $402.4M | $-271.1M | ||
| Q3 25 | $440.8M | $-274.1M | ||
| Q2 25 | $392.2M | $-354.6M | ||
| Q1 25 | $416.9M | $-341.8M | ||
| Q4 24 | $454.8M | $-326.4M | ||
| Q3 24 | $483.0M | $-292.3M | ||
| Q2 24 | $487.2M | $-241.3M | ||
| Q1 24 | $496.6M | $-201.4M |
总资产ACLXAGEN
| Q4 25 | $604.0M | $226.8M | ||
| Q3 25 | $655.9M | $233.9M | ||
| Q2 25 | $619.1M | $185.2M | ||
| Q1 25 | $648.1M | $200.2M | ||
| Q4 24 | $711.3M | $226.3M | ||
| Q3 24 | $764.9M | $238.5M | ||
| Q2 24 | $734.3M | $292.4M | ||
| Q1 24 | $779.7M | $256.6M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-58.2M | $-16.6M |
| 自由现金流经营现金流 - 资本支出 | $-58.9M | — |
| 自由现金流率自由现金流/营收 | -3563.4% | — |
| 资本支出强度资本支出/营收 | 46.2% | 0.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-212.6M | — |
8季度趋势，按日历期对齐
经营现金流ACLXAGEN
| Q4 25 | $-58.2M | $-16.6M | ||
| Q3 25 | $-49.2M | $-14.7M | ||
| Q2 25 | $-39.7M | $-20.2M | ||
| Q1 25 | $-63.1M | $-25.6M | ||
| Q4 24 | $-46.0M | $-28.7M | ||
| Q3 24 | $30.7M | $-53.3M | ||
| Q2 24 | $-36.2M | $-38.2M | ||
| Q1 24 | $-31.9M | $-38.2M |
自由现金流ACLXAGEN
| Q4 25 | $-58.9M | — | ||
| Q3 25 | $-49.5M | — | ||
| Q2 25 | $-40.2M | $-20.2M | ||
| Q1 25 | $-63.9M | $-25.6M | ||
| Q4 24 | $-47.5M | $-28.7M | ||
| Q3 24 | $28.4M | $-53.3M | ||
| Q2 24 | $-39.5M | $-38.6M | ||
| Q1 24 | $-38.3M | $-38.2M |
自由现金流率ACLXAGEN
| Q4 25 | -3563.4% | — | ||
| Q3 25 | -1000.3% | — | ||
| Q2 25 | -532.4% | -78.7% | ||
| Q1 25 | -786.4% | -106.5% | ||
| Q4 24 | -311.3% | -107.0% | ||
| Q3 24 | 109.2% | -212.2% | ||
| Q2 24 | -144.1% | -164.4% | ||
| Q1 24 | -97.7% | -136.5% |
资本支出强度ACLXAGEN
| Q4 25 | 46.2% | 0.0% | ||
| Q3 25 | 6.0% | 0.0% | ||
| Q2 25 | 6.4% | 0.0% | ||
| Q1 25 | 9.6% | 0.0% | ||
| Q4 24 | 9.8% | 0.3% | ||
| Q3 24 | 8.8% | 0.0% | ||
| Q2 24 | 11.7% | 2.0% | ||
| Q1 24 | 16.4% | 0.1% |
现金转化率ACLXAGEN
| Q4 25 | — | — | ||
| Q3 25 | — | -0.23× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
